Cogent Biosciences IncCOGT
Price$31.59

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $0TTM through 30 Jun 2026
Net Income -$377.2MTTM through 30 Jun 2026
Free Cash Flow -$309.2MTTM through 30 Jun 2026

Margins

Current

Returns

-70.8%ROE
-45.2%ROA

Balance Sheet Health

Debt / Equity0.08x
Current Ratio13.57x
Net Debt-$136.9Mnet cash position
Cash & Equivalents$181.2M

Quality Metrics

Altman Z-Score8.46
Piotroski F-Score1 / 9
Earnings-Beat Rate75.0%

Multi-Year Trend

Revenue
'17'18'19'20
FY2020: $7.9M
Diluted EPS-$2.16TTM
'21'22'23'24'25
FY2025: $-2.55

Dividend

No dividend

Capital Allocation

R&D Spend$290.7M

Segment Performance

No segment data available.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.